NA
VNDA icon

Neuburgh Advisers’s Vanda Pharmaceuticals VNDA Stock Holding History

Neuburgh Advisers’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$73K Buy
5,456
+256
+5% +$3.57K ﹤0.01% 820
2019
Q2 		$73K Buy
5,200
+144
+3% +$2.29K ﹤0.01% 832
2019
Q1 		$93K Hold
5,056
– – ﹤0.01% 798
2018
Q4 		$132K Buy
+5,056
New +$119K 0.01% 717

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Neuburgh Advisers's VNDA Position: Q3 2019 in Review

Neuburgh Advisers increased its Vanda Pharmaceuticals (VNDA) stake by 4.9% in Q3 2019, buying an estimated $3.57K and bringing the position to 5,456 shares worth $73K. The position accounts for ﹤0.01% of the portfolio, ranked #820.

Neuburgh Advisers first reported a position in VNDA in Q4 2018 and has held it in 4 quarters since. The position peaked at $132K in Q4 2018. 168 funds tracked by Wall St. Rank hold VNDA as of Q3 2019.

  • Neuburgh Advisers held 5,456 shares of Vanda Pharmaceuticals worth $73K as of Q3 2019.
  • Neuburgh Advisers bought 256 Vanda Pharmaceuticals shares in Q3 2019, an estimated $3.57K.
  • Vanda Pharmaceuticals made up ﹤0.01% of Neuburgh Advisers's portfolio in Q3 2019, its #820 holding.
  • Neuburgh Advisers first reported a position in Vanda Pharmaceuticals in Q4 2018 and has held it in 4 quarters since.
  • Neuburgh Advisers's Vanda Pharmaceuticals position peaked at $132K in Q4 2018.
  • 168 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2019.

Based on Neuburgh Advisers's 13F filing for Q3 2019, filed 14 Nov 2019.